Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP4 receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 6, 2008, Pages 2048-2054

  Burch, Jason D ^a   Belley, Michel ^a   Fortin, Réjean ^a   Deschênes, Denis ^a   Girard, Mario ^a   Colucci, John ^a   Farand, Julie ^a   Therien, Alex G ^a   Mathieu, Marie Claude ^a   Denis, Danielle ^a   Vigneault, Erika ^a   Lévesque, Jean François ^a   Gagné, Sébastien ^a   Wrona, Mark ^a   Xu, Daigen ^a   Clark, Patsy ^a   Rowland, Steve ^a   Han, Yongxin ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Anti inflammatories; Prostanoid receptor antagonists; Quinoline acylsulfonamides

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; MF 498; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTANOID RECEPTOR; QUINOLINE DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CHRONIC INFLAMMATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SYNTHESIS; HUMAN; MOUSE; NONHUMAN; PLASMA CLEARANCE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; DOGS; GUINEA PIGS; HUMANS; MACACA MULATTA; MOLECULAR STRUCTURE; QUINOLINES; RATS; RECEPTORS, PROSTAGLANDIN E; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 40749101646     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.01.103     Document Type: Article

References (28)

1. Flower R.J. Nat. Rev. Drug Disc. 2 (2003) 179
2. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Bosi Ferraz R., Hawkey C.J., Hochberg M.C., Kvien T.K., and Schnitzer T.J. N. Eng. J. Med. 343 (2000) 1520
3. Solomon S.D., McMurray J.J.V., Pfeiffer M.A., Wittes J., Fowler R., Finn P., Anderson W.F., Zauber A., Hawk E., and Bertagnolli M. N. Eng. J. Med. 352 (2005) 1071
4. Nussmeier N.A., Whelton A.A., Brown M.T., Langford R.M., Hoeft A., Parlow J.L., Boyce S.W., and Verbug K.M. N. Eng. J. Med. 352 (2005) 1081
5. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., Lines C., Ridell R., Morton D., Lanas A., Konstam M.A., and Baron J.A. N. Eng. J. Med. 352 (2005) 1092
6. McAdam B.F., Catella-Lawson F., Mardini I.A., Kapoor S., Lawson J.A., and FitzGerald G.A. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 272
7. FitzGerald G.A., and Patrono C. N. Eng. J. Med. 345 (2001) 433
8. For a recent review see:. Funk C.D., and FitzGerald G.A. J. Cardiovasc. Pharm. 50 (2007) 470
9. McCoy J.M., Wicks J.R., and Audoly L.P. J. Clin. Invest. 110 (2002) 651
10. Lin C.-R., Amaya F., Barrett L., Wang H., Takada J., Samad T.A., and Woolf C.J. J. Pharmacol. Exp. Ther. 319 (2006) 1096
11. Cipollone F., Fazia M.L., Iezzi A., Cuccurollo C., De Cesare D., Ucchino S., Spigonardo F., Marchetti A., Buttitta F., Paloscia L., Mascellanti M., Cuccurollo F., and Mezzetti A. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1925
12. Ma X., Kundu N., Rifat S., Walser R., and Fulton A.M. Cancer Res. 66 (2006) 2923
13. Chell S.D., Witherden I.R., Dobson R.R., Moorghen M., Herman A.A., Qualtrough D., Williams A.C., and Paraskeva C. Cancer Res. 66 (2006) 3106
14. Yang L., Huang Y., Porta R., Yanagisawa K., Gonzalez A., Segi E., Johnson D.J., Narumiya S., and Carbone D.P. Cancer Res. 66 (2006) 9665
15. Wilson R.J., Giblin G.M.P., Roomans S., Rhodes S.A., Cartwright K., Shield V.J., Brown J., Wise A., Chowdhury J., Pritchard S., Coote J., Noel L.S., Kenakin T., Burns-Kurtis C.L., Morrison V., Gray D.W., and Giles H. Br. J. Pharmacol. 148 (2006) 326
16. 4 antagonists from the literature see:. Brittain R.T., Boutal L., Carter M.C., Coleman R.A., Collington E.W., Geisow H.P., Hallett P., Hornby E.J., Humphrey P.P., Jack D., Kennedy I., Lumley P., McCabe P.J., Skidmore I.F., Thomas M., and Wallis C.J. Circulation 72 (1985) 1208
17. Machwate M., Harada S., Leu C.T., Seedor G., Labelle M., Gallant M., Hutchins S., Lachance N., Sawyer N., Slipetz D., Metters K.M., Rodan S.B., Young R., and Rodan G.A. Mol. Pharmacol. 60 (2001) 36
18. Mutoh M., Watanabe K., Kitamura T., Shoji Y., Takahashi M., Kawamori T., Tani K., Kobayashi M., Maruyama T., Kobayashi K., Ohuchida S., Sugimoto Y., Narumiya S., Sugimura T., and Wakabayashi K. Cancer Res. 62 (2002) 28
19. Hattori K., Tanaka A., Fuji N., Takasugi H., Tenda Y., Tomita M., Nakazato K., Kato Y., Kono Y., Murai H., and Sakane K. J. Med. Chem. 48 (2005) 3103
20. Nakao K., Murase A., Ohshiro H., Okumura T., Taniguchi K., Murata Y., Masuda M., Kato T., Okumura Y., and Takada J. J. Pharmacol. Exp. Ther. 322 (2007) 686
21. Abramovitz M., Adam M., Boie Y., Carriere M., Denis D., Godbout C., Lamontagne S., Rochette C., Sawyer N., Tremblay N.M., Belley M., Gallant M., Dufresne C., Gareau Y., Ruel R., Juteau H., Labelle M., Ouimet N., and Metters K.M. Biochem. Biophys. Acta 1483 (2000) 285
22. Data not shown; for functional assay details see Ref. 15.
23. Homeyer W. J. Am. Chem. Soc. 64 (1942) 798
24. Johnson T.B., and Sprague J.M. J. Am. Chem. Soc. 58 (1936) 1348
25. More detailed experimental procedures can be found in: Belley, M.; Burch, J.; Colucci, J.; Farand, J.; Girard, M.; Han, Y. WO Patent 2006122403; Chem. Abstr. 2006, 145, 505342.
26. Mathieu, M.-C. et al. and Clark, P. et al. (in preparation).
27. Slipetz D., Buchanan S., Mackereth C., Brewer N., Pellow V., Hao C.-M., Adam M., Abramovitz M., and Metters K.M. Biochem. Pharmacol. 62 (2001) 997
28. Chan C.-C., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., Evans J., Ford-Hutchinson A.W., Forrest M.J., Gauthier J.Y., Gordon R., Gresser M., Guay J., Kargman S., Kennedy B., Leblanc Y., Léger S., Mancini J., O'Neill G.P., Ouellet M., Patrick D., Percival M.D., Perrier H., Prasit P., Rodger I., Tagari P., Therien M., Vickers P., Visco D., Wang Z., Webb J., Wong E., Xu L.-J., Young R.N., Zamboni R., and Riendeau D. J. Pharmacol. Exp. Ther. 290 (1999) 551